a) BMI % stratified by dose and rs10305420 genotype for tirzepatide, as measured in individuals of European ancestry
GLP-1(936) also potently inhibited glucagon secretion evoked by -adrenergic stimulation, amino acids and membrane depolarisation
147,179,180,184 Clinical follow-up also shows that despite standardized supplementation, RYGB and BPD patients have more pronounced and persistent bone loss compared to other procedures
D.HaranO.Smith-MontesE.ZivanovicO.et al (2024)
Yes, injection site selection does matter when administering glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), or liraglutide (Victoza, Saxenda)
GLP-1 plays into this communication system